《大行報告》花旗:中國建築國際(03311.HK)成功轉型料營運現金流維持正數 列行業首選
花旗發表報告,指中國建築國際(03311.HK)近期成功轉型,料營運現金流維持正數。公司冀長遠在內地業務取得正營運現金流,而非依靠澳門和香港市場。該行相信其2022年上半年所錄正營運現金流是可持續,將其列入行業首選。該行予其目標價15元,評級「買入」。
花旗認為,中國建築國際將盈利增幅指引由雙位數上調至15%,反映內地和香港均有強勁需求,將於今年10月公布的新一份《施政報告》料屬正面催化劑,因憧憬有新基建及房屋項目宣布。另內地進一步採用組裝合成建築法,及香港和澳門可能採用建築整合太陽能,認為中國建築國際是投資內地ESG建築的良好替代標的。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.